Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Special report
: The Fierce 50 of 2024
ATTR
Pharma
Pfizer's ATTR drug needs hefty discount, says ICER draft report
ICER also conducted a preliminary analysis of Alnylam’s Amvuttra, which recently reported a positive phase 3 readout in ATTR-CM.
Angus Liu
Jul 18, 2024 4:37pm
Alnylam touts 'big-win scenario' for closely watched heart trial
Jun 24, 2024 10:53am
Experts paint tough path ahead of Alnylam's key ATTR-CM readout
Apr 22, 2024 10:55am
Alnylam embarks on campaign to drive hATTR amyloidosis diagnoses
Mar 13, 2024 10:30am
Alnylam's last-minute Amvuttra trial change raises doubts
Feb 15, 2024 11:26am
FDA spurns Alnylam's Onpattro in ATTR-CM despite adcomm backing
Oct 9, 2023 9:54am
